Rational design of antisense oligomers to induce dystrophin exon skipping.
about
Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patientEmerging genetic therapies to treat Duchenne muscular dystrophyIn-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.Variants affecting exon skipping contribute to complex traits.The status of exon skipping as a therapeutic approach to duchenne muscular dystrophyImproved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophyEvaluation of exon-skipping strategies for Duchenne muscular dystrophy utilizing dystrophin-deficient zebrafish.A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.Multiple exon skipping strategies to by-pass dystrophin mutations.Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agentsAntisense suppression of donor splice site mutations in the dystrophin gene transcript.The genetic basis for individual differences in mRNA splicing and APOBEC1 editing activity in murine macrophages.Targeting RNA to treat neuromuscular disease.Translational development of splice-modifying antisense oligomers.Modulation of p53 expression using antisense oligonucleotides complementary to the 5'-terminal region of p53 mRNA in vitro and in the living cells.Alzheimer's disease-related peptide PS2V plays ancient, conserved roles in suppression of the unfolded protein response under hypoxia and stimulation of γ-secretase activity.Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.
P2860
Q28475196-138A9307-F403-4D2A-826A-3E3698E7B00DQ33796975-84B7B5EC-4B28-4941-9F25-3B7B2883741AQ34343780-02B4D01C-C5C9-4A7C-8128-5362AE4F2055Q34469030-60BEF949-6FD1-4F52-B6B9-DDABD9639E41Q34473336-C8F92C7A-3E7E-49ED-858B-9309B28D1284Q34695728-15D428BC-D42B-432B-B77E-6DCC0FBE8D29Q35216325-1D11C4DD-58BD-4CA1-8F04-A76F9A274719Q36114216-FC546415-0D85-4EB6-90B2-07CEBBD1A658Q36369845-CEB80179-DB52-46D8-9761-1EF2433D89B8Q36925191-C8914215-4FCA-4264-AE32-6E58685FB20BQ37398103-B40D6BCB-1A72-438E-82AE-E4A96ED9808DQ37614934-3E04FA97-9595-42AB-995A-9A15B54B26D6Q37909000-F21942BF-1FD3-4A88-86D5-7A6260E6FBE1Q38996657-FC88327B-DD73-454D-90F2-0145176D6141Q39062038-6F668635-EEF8-4FA2-80A1-60262BCE0981Q41151649-E78717EB-330C-4AF8-88B9-5FC49DB963A5Q44671291-593575F5-9C61-415B-AAD2-E2FF18835403
P2860
Rational design of antisense oligomers to induce dystrophin exon skipping.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Rational design of antisense oligomers to induce dystrophin exon skipping.
@ast
Rational design of antisense oligomers to induce dystrophin exon skipping.
@en
type
label
Rational design of antisense oligomers to induce dystrophin exon skipping.
@ast
Rational design of antisense oligomers to induce dystrophin exon skipping.
@en
prefLabel
Rational design of antisense oligomers to induce dystrophin exon skipping.
@ast
Rational design of antisense oligomers to induce dystrophin exon skipping.
@en
P2093
P2860
P356
P1433
P1476
Rational design of antisense oligomers to induce dystrophin exon skipping
@en
P2093
Abbie M Adams
Francesco Muntoni
Penny L Meloni
Steve D Wilton
P2860
P304
P356
10.1038/MT.2009.49
P577
2009-03-17T00:00:00Z